X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Hua Medicine shall be responsible for clinical development, registration, product supply and distribution of dorzagliatin, whilst Bayer as the promotion service provider shall be responsible for marketing, promotion and medical education activities in China.
Lead Product(s): Dorzagliatin
Therapeutic Area: Endocrinology Product Name: HMS5552
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $635.8 million Upfront Cash: $43.3 milllion
Deal Type: Partnership August 17, 2020
Details:
All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. Study met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial.
Lead Product(s): Dorzagliatin,Metformin
Therapeutic Area: Endocrinology Product Name: HMS5552
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.
Lead Product(s): Dorzagliatin,Empagliflozin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
